Aarti Pharmalabs Limited (NSE:AARTIPHARM)
India · Delayed Price · Currency is INR 1,013.00
+89.50 (9.69%)
Nov 12, 2026, 3:29 PM IST
Aarti Pharmalabs Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 91,859 | 53,665 | 67,908 | 39,418 | 24,999 | - | |
Market Cap Growth | 32.28% | -20.97% | 72.28% | 57.68% | - | - |
Enterprise Value | 99,700 | 59,857 | 70,778 | 40,892 | 26,947 | - |
Last Close Price | 1010.50 | 590.52 | 743.84 | 429.65 | 271.44 | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 44.90 | 30.72 | 24.93 | 18.17 | 12.92 | - |
PS Ratio | 4.67 | 2.95 | 3.21 | 2.13 | 1.29 | - |
PB Ratio | 4.32 | 2.53 | 3.41 | 2.24 | 1.60 | - |
P/TBV Ratio | 4.59 | 2.68 | 3.59 | 2.35 | 1.65 | - |
P/FCF Ratio | - | - | - | 64.89 | 16.89 | - |
P/OCF Ratio | 35.07 | 20.49 | 20.57 | 18.22 | 9.99 | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 5.06 | 3.29 | 3.35 | 2.21 | 1.39 | - |
EV/EBITDA Ratio | 21.83 | 15.77 | 15.59 | 10.75 | 7.88 | - |
EV/EBIT Ratio | 28.86 | 20.08 | 18.75 | 13.07 | 9.64 | - |
EV/FCF Ratio | - | - | - | 67.31 | 18.21 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.37 | 0.36 | 0.21 | 0.16 | 0.14 | 0.25 |
Debt / EBITDA Ratio | 1.81 | 1.95 | 0.92 | 0.74 | 0.63 | 1.65 |
Debt / FCF Ratio | - | - | - | 4.70 | 1.46 | - |
Net Debt / Equity Ratio | 0.37 | 0.36 | 0.18 | 0.11 | 0.10 | 0.19 |
Net Debt / EBITDA Ratio | 1.78 | 2.00 | 0.80 | 0.50 | 0.45 | 1.25 |
Net Debt / FCF Ratio | - | -5.16 | -5.08 | 3.14 | 1.03 | -1.40 |
Asset Turnover | - | 0.57 | 0.77 | 0.77 | 0.91 | 1.18 |
Inventory Turnover | - | 1.44 | 1.83 | 1.70 | 2.24 | - |
Quick Ratio | - | 0.64 | 0.98 | 0.90 | 0.86 | 0.80 |
Current Ratio | - | 1.49 | 2.02 | 1.94 | 1.94 | 1.77 |
Return on Equity (ROE) | - | 8.49% | 14.54% | 13.08% | 13.14% | 17.63% |
Return on Assets (ROA) | - | 5.84% | 8.60% | 8.10% | 8.16% | 10.10% |
Return on Invested Capital (ROIC) | 8.50% | 8.53% | 13.25% | 12.34% | 12.36% | 7.89% |
Return on Capital Employed (ROCE) | - | 11.70% | 16.80% | 16.60% | 17.00% | 11.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.23% | 3.26% | 4.01% | 5.50% | 7.74% | - |
FCF Yield | -1.61% | -2.75% | -1.06% | 1.54% | 5.92% | - |
Dividend Yield | 0.35% | 0.59% | 0.67% | 0.69% | 0.73% | - |
Payout Ratio | 15.51% | 20.75% | 11.64% | 8.36% | 9.37% | - |
Buyback Yield / Dilution | -0.11% | -0.05% | -0.07% | -0.01% | - | -36150.40% |
Total Shareholder Return | 0.24% | 0.55% | 0.60% | 0.68% | 0.73% | -36150.40% |